Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product ...

Just over two years after establishing desmoidtumors.com, the drugmaker is teaming with Jennifer Fisher to empower patients.

SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q4 2024 earnings on February 20, 2025. The consensus estimate for Q4 2024 revenue is $59.12 million, and the earnings are expected to ...

Reports FY24 revenue $191.5M, consensus $190.85M. “We are very pleased with the strong execution of OGSIVEO in 2024 and believe that we are ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aura Biosciences Inc (AURA – Research Report) ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...

SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor ...

The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

"Onco360 is grateful for the opportunity to partner on another therapy with the team at SpringWorks Therapeutics and become a ...